Navigation Links
NIDA Avant-Garde-Medications Development Award winners announced
Date:9/20/2011

Scientists proposing to develop vaccines against methamphetamine and nicotine have been selected to receive NIDA's second Avant-Garde Awards for Innovative Medication Development Research. The two scientists, Dr. Thomas Kosten, of Baylor College of Medicine, Houston, and Dr. Peter Burkhard, of the University of Connecticut, Storrs, will each receive $500,000 per year for five years to support their research, according to the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

"Through this funding opportunity, NIDA once again strengthens its commitment toward developing safe and efficacious medications to treat addiction," said NIDA Director Nora D. Volkow, M.D. "This program expressly seeks to promote research projects that are ready for clinical translation and can accelerate the development of new medications."

Awardees are listed below:

Awardee: Thomas Kosten, Ph.D., Baylor College of Medicine
Project: Human methamphetamine vaccine

Dr. Kosten's group will accelerate the development of a methamphetamine vaccine, which is expected to undergo initial clinical trials within the next five years. At present there is no FDA-approved medication for methamphetamine addiction, so a vaccine could have substantial impact on the treatment of methamphetamine addiction.

Awardee: Peter Burkhard, Ph.D., University of Connecticut
Project: A peptide nanoparticle nicotine vaccine

Dr. Burkhard's lab plans to develop and test a novel type of vaccine that induces a strong immune response against nicotine without the need of chemical enhancers, which could result in a less expensive vaccine with fewer side effects. This nicotine vaccine will be administered intranasally, which will be more convenient and less painful than an injection. The new vaccine is expected to enter initial clinical trials within the next five years.

"Not only do these grantees have a strong background in vaccine research, but they also have clear plans for initiating clinical trials within an accelerated period of time," said Dr. Volkow. "They clearly represent the goal of the Avant-Garde program to support investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on the treatment of drug abuse."


'/>"/>

Contact: NIDA Press Team
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse
Source:Eurekalert

Related medicine news :

1. Transformative NIH grant will support development of tissue regeneration therapeutics
2. New strategy likely to speed drug development for rare cancers
3. Prenatal exposure to phthalates linked to decreased mental and motor development
4. Memory Development Incomplete Until Adulthood: Study
5. Researchers developing new test to measure risk for birth defects and neuro-developmental disorders
6. Sweet insight: Discovery could speed drug development
7. AMRI receives NIH contract award for development of pre-clinical drug candidates
8. NIH Blueprint empowers drug development for nervous system disorders
9. Penn researchers describe key molecule that keeps immune cell development on track
10. Sharing Bed With Toddler Wont Harm Development: Study
11. DNDi launches new drug development program to address treatment needs of children with HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... City, CA (PRWEB) , ... December 07, 2016 , ... ... during the holidays and winter seasons. One major study analyzing heart attacks among ... compared to August of a given year. We would all agree of course–no time ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX ... media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes ... use drop zones. Editors can select from a variety of flip book animations. In ...
(Date:12/7/2016)... CINCINNATI, Ohio (PRWEB) , ... December 07, 2016 ... ... winner in the 2016 BOC Business Brilliance Awards under the Best New Product ... inception and results achieved through user experience. , BOC Global Events & Training ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... is bringing their 100% all-natural lice removal service to ... 13 th Street was specifically chosen to make treatment convenient ... goal is to ease parents, stress and bring their lives back ... back to class without skipping a beat. The best part is ... whole family," Licenders President Adie Horowitz states. ...
(Date:12/6/2016)... , Dec. 6, 2016  Alopexx Oncology, LLC announced ... recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 and ... same target on B cells as Rituxan and maintains ... but is also involved in tumor targeting, engagement of ... effect. The results of the study (abstract #95954) were ...
(Date:12/6/2016)... 2016  "Blood Tests replace Surgical Biopsies. Single ... The Diagnostic, Monitoring and Screening Test opportunities are ... occurring using in vitro blood testing to identify ... backing, has announced a single blood test to ... than the market. New technology that definitively identifies ...
Breaking Medicine Technology: